Catching up with Keytruda, Regeneron scores frontline NSCLC approval for Libtayo/chemo combo

Regeneron’s Libtayo has made it into the exclusive club of PD-(L) inhibitors approved, in combination with chemotherapy, as a frontline treatment for a broad swath of lung cancer patients.